Advanced Filters
noise
Found 890 clinical trials
W Watcharasak Chotiyaputta, Asso Prof

Cardiovascular Risk Assessment and Coronary Calcium Score in Thai MASLD Patients

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in Thailand and is strongly linked to metabolic risk factors such as obesity, diabetes, hypertension, and dyslipidemia. Cardiovascular disease is the leading cause of death among patients with MASLD. Coronary artery calcium (CAC) scoring is a widely used marker of subclinical coronary …

35 - 75 years of age All Phase N/A
S Sebastian Heyne, Dr. med.

Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)

The aim of this study is to evaluate the effect of offering intrahospital influenza vaccination as an adjunct to active counseling during the index hospitalization to adult patients hospitalized for acute coronary syndrome (ACS) or congestive heart failure (CHF), compared with active counseling alone, on influenza vaccination rates in patients …

18 years of age All Phase N/A
S Susan Mackness

Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction

There is an epidemic of type 2 diabetes in younger adults. These patients are at very high lifetime risk of heart-related complications. Subtle heart abnormalities can be present even at a young age in these patients and may predispose them to heart failure and ultimately premature death. There is emerging …

18 - 65 years of age All Phase N/A

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin …

45 - 80 years of age All Phase N/A

A Longitudinal Study to Identify Mechanisms of Menopause on Cardiovascular Disease Risk

With the cessation of estrogen production at menopause, the risk of cardiovascular disease like arthrosclerosis, myocardial infarction and stroke increases dramatically. Physical activity is the single most powerful "drug" for maintaining and improving cardiovascular health, but recent data suggest that the positive effect of physical activity is lost at menopause. …

40 - 61 years of age Female Phase N/A
c chi fu chiang, Ph.D

The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors

To assess the efficacy evaluation of buckwheat husk extract on cardiovascular disease risk factors

20 - 65 years of age All Phase N/A
A Alexander Egbe, MBBS, MPH

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.

18 years of age All Phase 3
M MeiChen Huang

Circulating microRNAs and Adverse Cardiovascular Outcomes in Patients With Coronary Artery Disease

Coronary artery disease (CAD) resulting from atherosclerotic obstruction of epicardial coronary arteries accounts for more than one-third of deaths in subjects over the age of 35 worldwide. The global incidence of CAD is on the rise owing to the international epidemic of obesity, type 2 diabetes and aging, all of …

20 years of age All Phase N/A
J Joaquim MATEO, MD

Prediction Models for Cardiovascular and Neurocognitive Disease Risk in the General Population

More accurate and earlier identification of people at risk of cardiovascular disease (CVD) and neurodegenerative diseases (memory, cognition, dementia) through the appropriate use of biomarkers could lead to earlier initiation of preventive therapies and potentially avoid sometimes fatal events and complications. Biomarkers are useful for determining the risk of disease, …

45 years of age All Phase N/A
V Valentina Ruggieri, SC

Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

Observational study on the influence of frailty on cardiovascular risk in COPD.

40 years of age All Phase N/A

Simplify language using AI